Detechgene successfully completes second seed financing round.
Cologne based biotechnology company Detechgene announces the successful completion of its second seed financing round, raising 3 million €. With this fresh capital, Detechgene is consistently pursuing its vision: to make laboratory diagnostics accessible to everyone – fast, mobile and reliable.
Detechgene welcomes Neoteq Ventures, an experienced early-stage investor with a strong focus on technology-driven start-ups, as its new lead investor. The round is also supported by NRW.BANK, Aquarius Invest, Meerkat Holding GmbH, Campus Capital and several strategic business angels who bring valuable expertise and a strong network to the table.
Dr. Christoph Labisch (Managing Director, Aquarius Invest GmbH):"The successful completion of this financing round sends a strong signal: Detechgene is bringing molecular diagnostics where it is needed – quickly, accurately and on the go. The team not only delivers excellent technology, but has also demonstrated its ability to scale. We at Aquarius Invest are delighted to be part of this development.
Especially in times when the healthcare system is facing growing challenges, flexible, smart solutions are needed. Detechgene has the potential to permanently change diagnostics – not only in Germany, but also internationally.‘
’We are very grateful to our investors for their confidence in our team and our technology. Together, we are shaping the future of diagnostics – faster, more decentralised and more user-friendly than ever before," says Dr. Reza Esmaillie, Managing Director of Detechgene.
With its innovative rapid test system ‘PCR to Go’, Detechgene is developing a mobile molecular biology diagnostics solution that can be used anywhere and detects a wide range of pathogens within a very short time.
